Background: Community-acquired pneumonia (CAP) is a frequent event in patients with COPD, although it is not currently considered an acute exacerbation of COPD (AECOPD). To our knowledge, no studies have compared the infl ammatory response of patients with COPD who develop CAP or AECOPD. The aim of our study was to compare clinical and evolutive manifestations and biologic signaling of AECOPD and CAP 1 COPD. Methods: Prospective data were collected from 249 consecutively hospitalized patients with COPD. Comparative analyses were performed in patients with AECOPD (n 5 133) and patients with CAP 1 COPD (n 5 116). Measures of clinical characteristics, blood biomarkers, and evolution were recorded on admission, after 3 and 30 days, and in a follow-up period of 30 days, 90 days, and 1 year. Results: Patients with CAP 1 COPD had higher FEV 1 compared with patients with COPD without pneumonia. In-hospital and long-term outcomes (1 year) were similar for both populations. However, patients with AECOPD had more readmissions, and patients with CAP had more prior episodes of pneumonia. At day 1 and day 3, patients with CAP 1 COPD had signifi cantly ( P , .001) higher serum levels of C-reactive protein (CRP), procalcitonin, tumor necrosis factor-a , and IL-6. Repetition of the analyses after stratifying patients based on severity of disease, current inhaled pharmacotherapy, and noninfectious AECOPD cause confi rmed higher levels of the same biomarkers in patients with CAP 1 COPD. Chills, pleuritic pain, sputum purulence, and CRP levels at day 1 were independent clinical predictors of CAP 1 COPD. Conclusions: Our study confi rms that two different clinical and infl ammatory profi les exist in hospitalized patients with COPD in response to CAP (stronger response) and AECOPD, although with similar short-term and long-term outcomes.
OPD is a growing cause of disease worldwide 1 : according to the Epidemiologic Study of COPD in Spain (EPI-SCAN) study, the prevalence of COPD in Spain is estimated at 10.2%. 2 Acute exacerbation of COPD (AECOPD) is an event that occurs in the natural course of COPD and requires hospitalization. 3 AECOPD accelerates the decline in lung function 4 and increases risk of death. 5 According to the criteria of Anthonisen et al, 6 AECOPD is defi ned clinically by three symptoms: increased shortness of breath, increased sputum volume, and purulence. Studies have shown that patients with frequent AECOPD compose a specifi c COPD phenotype. 7 Community-acquired pneumonia (CAP) is an infectious disease that is highly prevalent in patients with COPD 8, 9 and is probably linked to abnormal host defense mechanisms. 10, 11 Elsewhere, we have shown that hospitalized patients with CAP with COPD (CAP 1 COPD) have a different and specifi c early infl ammatory response compared with patients without COPD. 12 Clinically, in patients with COPD, CAP is not currently considered an exacerbation, even though several microorganisms such as C pneumoniae ( Ն 1:32), C burnetii ( Ն 1:80), and M pneumoniae (any positive titer).
Clinical Evaluations and Determination of Blood Biomarkers
Data on demographic variables were recorded on admission. Symptoms and signs of an acute event together with physiologic and laboratory data were collected at onset. Length of stay (LOS), admission to the ICU, or noninvasive mechanical ventilation (NIMV), and frequency of patients in whom severe sepsis with or without septic shock was identifi ed were also recorded. Mortality and rehospitalization were evaluated during follow-up (30 and 90 days and 1 year). Measurements of C-reactive protein (CRP), procalcitonin (PCT), tumor necrosis factor-a (TNF-a ), and cytokines (IL-1, IL-6, IL-8, and IL-10) were performed on admission and at 3 and 30 days thereafter.
Statistical Analysis
Analysis of variables was performed using a statistical software package (SPSS 17; IBM). Results were expressed as mean Ϯ SD or as median (25th-75th percentiles) for continuous variables and as frequency (percentage) for categorical variables.
A prior test for normal data distribution was performed (Kolmogorov-Smirnov test). Differences in continuous variables were analyzed using an independent two-tailed t test for unpaired analysis; otherwise, the nonparametric Mann-Whitney U or KruskalWallis tests were used. Categorical variables were studied using the x 2 test or Fisher exact test when necessary.
To characterize early predictors of a specifi c group of patients, a multivariate analysis of signifi cant clinical and infl ammation variables was performed using a stepwise logistic regression model with AECOPD/CAP 1 COPD as a binary dependent variable; continuous variables were categorized by quartiles. A HosmerLemeshow goodness-of-fi t test was also calculated. Finally, the area under a receiver operating characteristic curve (AUC) measured the diagnostic discrimination property of signifi cant predicting biomarkers. For all analyses, P , .05 was considered to be statistically signifi cant. patients present repeated episodes during the course of the disease. 12 Moreover, in clinical practice, it is not always easy to determine whether patients with COPD have pneumonia or a bronchial infection. Measurement of increasing plasma levels of infl ammatory biomarkers from the stable condition can be useful to identify an exacerbation and predict mortality 13 ; in addition, no studies have compared the infl ammatory response of patients with COPD who develop CAP 1 COPD and those who develop AECOPD. The aim of our study was to compare the clinical characteristics, systemic infl ammatory profi le, and short-term and long-term evolution between the two groups: CAP 1 COPD and AECOPD.
Materials and Methods

Study Cohort and Defi nitions
We performed a prospective study of consecutive adult patients with COPD hospitalized at two tertiary university hospitals in Spain (Hospital La Fe, Valencia and Hospital Clinic, Barcelona). The study was approved by the ethics committees (Project CEIC 2003/0048 and CEIC 2004/1855 for Hospital La Fe and Hospital Clinic, respectively) in accordance with the Declaration of Helsinki. Written informed consent was obtained from patients. Figure 1 shows the study fl ow diagram. A complete description of COPD, CAP, and AECOPD and sepsis and septic shock defi nitions are provided in e-Appendix 1 .
Microbiologic Evaluation
We attempted to obtain sputum of good quality for bacterial and fungal culture in patients with AECOPD. The microbiologic samples of patients with CAP included sputum samples, two blood cultures, and detection of urinary antigens for Streptococcus pneumoniae and Legionella pneumophila . Diagnosis of the following microorganisms was also carried out by pairing sera on admission and 3 and 6 weeks after admission: (1) the potential effect of home-based pharmacotherapy (for short-acting bronchodilators, data not shown; for inhaled corticosteroids [ICSs], see Fig 3 ) confi rmed higher levels of CRP, PCT, TNF-a , and IL-6 in patients with CAP 1 COPD, especially on admission (day 1 and day 3).
The logistic regression analysis ( Fig 4 ) performed with the specifi c diagnosis (AECOPD or CAP 1 COPD) as a dependent variable and adjusted for descriptive confounders (GOLD [Global Initiative for Chronic
Results
Data on 249 patients with COPD admitted to two tertiary university hospitals were collected. Of these, 133 patients (53%) were considered to have AECOPD, and 116 patients (47%) had CAP associated with COPD. Severity of COPD according to lung function (mean FEV 1 , 47% Ϯ 16% predicted), number of patients requiring long-term oxygen therapy (n 5 27, 20.3%), and use of short-acting bronchodilators were greater in patients with AECOPD. Table 1 shows the main characteristics.
Clinical features of patients with COPD at hospitalization and during follow-up ( Tables 2, 3 ) were as follows: Patients with CAP 1 COPD had higher prevalence of symptoms/signs (fever, chills, sputum purulence, pleuritic pain) and severe sepsis, whereas patients requiring NIMV and patients readmitted in a period of 30 days were more prevalent in the AECOPD group. Other characteristics of clinical severity (Pa o 2 /F io 2 , LOS, admission to ICU, and septic shock) were similar in both groups. Furthermore, the mortality calculated on hospitalization and at 30 and 90 days and at 1 year was also similar. The prevalence of recurrent acute events showed a higher proportion of patients with a prior episode of pneumonia in patients with CAP 1 COPD ( P , .001) and more patients with more than two exacerbations per year in the AECOPD group ( P , .01 for both variables in comparison with CAP 1 COPD) ( Fig 2 ) .
Rate of microbiologic diagnosis ( Table 2 ) was confi rmed in 44% and 47% of patients with AECOPD and patients with CAP 1 COPD, respectively. In the etiology comparison, Haemophilus infl uenzae was more prevalent in AECOPD (19% vs 5% of CAP 1 COPD, P 5 .04), whereas S pneumoniae was more prevalent in CAP 1 COPD (43% vs 10% of AECOPD, P , .001). Other microbial causes were similar between groups.
On admission and 3 days afterward, patients with CAP 1 COPD had signifi cantly higher biologic signaling in comparison with patients with AECOPD ( P , .001 for CRP, PCT, TNF-a , IL-6; P , .05 for IL-1, IL-8). On day 30, levels of IL-6 were higher ( P , .05) in patients with CAP 1 COPD. The remain ing IL-10 level was similar in both groups ( Table 4 ) .
A new analysis performed with the exclusion of patients without a confi rmed infectious cause from the AECOPD group (AECOPD, n 5 59; CAP 1 COPD, n 5 116) (e- Table 1) showed similarly higher levels of biomarkers in the CAP 1 COPD group ( P , .001 for CRP, TNF-a , IL-6; P , .05 for PCT).
Analysis of signaling according to the severity of airfl ow obstruction confi rmed higher levels of CRP, PCT, TNF-a , and IL-6 ( P , .05) in patients with CAP 1 COPD in comparison with AECOPD (e- Table 2 ). Repetition of the analyses of biomarkers based on 0.71; 95% CI, 0.65-0.78; P , .001) with a best cutoff of 12.9 mg/dL (0.623 and 0.628 in the sensitivity and specifi city evaluation) ( Fig 5 ) .
Discussion
The main fi ndings of this study are as follows: (1) The clinical characteristics of both patients with AECOPD and patients with CAP 1 COPD on admission were different. Patients with AECOPD had greater severity of disease than patients with CAP 1 COPD. (2) Bacterial microbiology was different, with a predominance of H infl uenzae in the AECOPD group and S pneumoniae in the CAP 1 COPD group. (3) Despite different levels of severity of COPD, short-term and Obstructive Lung Disease] classifi cation, current domiciliary use of short-acting bronchodilators, and infectious cause) showed that clinical symptoms/signs (chills, pleuritic pain, and purulence sputum production) were clinical predictors for performing early discrimination of patients with CAP 1 COPD from patients with AECOPD. Moreover, CRP on day 1 (levels categorized by quartiles with Յ 3.5 mg/dL, fi rst quartiles used as references; 3.6-11.9 mg/dL, second quartiles; 12-20.4 mg/dL, third quartiles; Ն 20.5 mg/dL, fourth quartiles) showed an increasing OR in the prediction of CAP (OR, 4.02; 95% CI, 1.8-9.9; OR, 5.75; 95% CI, 3.2-12.7; and OR, 10.6; 95% CI, 4-25.4 in the second, third, and fourth quartiles, respectively; P , .001 for all quartiles). The accuracy analysis of CRP on day 1 showed a signifi cant predictive discrimination (AUC, logic response may be used as diagnostic marker in some cases in which the infi ltrates on the chest radiograph are in doubt.
Clinical and Microbiologic Differences
The functional characteristics of the two cohorts studied were dissimilar, as the AECOPD cohort included patients with more severe disease. We also observed differences, with more pleuritic pain, fever, chills, and leukocytosis in the CAP 1 COPD group. However, the severity of the acute disease was similar in terms of oxygenation and ICU admission. A prior study with a smaller number of patients, published . 10 years ago and comparing similar cohorts, found the same FEV 1 for both populations. 14 We do not have a clear explanation for this discrepancy, but it may be that patients hospitalized with AECOPD . 10 years ago had less severe disease than now (in terms of FEV 1 ).
Regarding microbiologic cause, our study confi rms the different and specifi c prevalence of pathogens in patients with AECOPD and patients with CAP 1 COPD 15 : More H infl uenzae was associated with AECOPD, 16 whereas pneumococcal causes were more frequent in cases of pneumonia. P aeruginosa long-term outcomes, including mortality, were similar. The only exception was the readmission rate in patients with AECOPD compared with patients with CAP 1 COPD (24% and 12%, respectively). (4) We showed that bacterial pneumonia infection produces more powerful biologic signaling, mediated by several biomarkers (CRP, PCT, TNF-a , and IL-6): This response is not infl uenced by severity of COPD or the use of current pharmacotherapy, particularly inhaled corticosteroids, or presence of infectious cause. (5) In our multivariate model, we showed that, in addition to initial symptoms, such as chills, pleuritic pain, and purulence of sputum, higher levels of CRP on admission is a strong predictor for discriminating CAP 1 COPD from AECOPD; this characteristic bio- Values are reported as median (25th-75th percentiles). CRP 5 C reactive protein; PCT 5 procalcitonin; TNF-a 5 tumor necrosis factor-a . See Table 1 legend for expansion of other abbreviations.
exacerbation on patients survival, showed that mortality 6 months after discharge from the hospital among patients readmitted one, two, or more times was 27%, 31%, and 36%, respectively, whereas those requiring no readmission had a mortality rate of 21%. 5 Methodologic differences in data collection might explain our results on lower mortality at 1 year of follow-up but undoubtedly require further studies. The only difference observed was a 24% readmission rate for patients with AECOPD compared with 12% for patients with CAP 1 COPD. This is probably explained by a higher baseline level of COPD severity in patients with AECOPD. In addition, this is a major issue in terms of health-care cost. Studies identifying risk factors for short-term readmission are needed in both populations. was similarly distributed. These differences may be explained by the different periods of COPD evolution.
Outcomes
Although this study is not powered for mortality, we found that mortality rates during hospitalization and in short-term and long-term follow-up were similar between groups, despite higher COPD functional severity of AECOPD compared with CAP 1 COPD, but lower than expected for both populations. For example, at 1 year, we observed 15% and 12% mortalities when comparing AECOPD to CAP 1 COPD, respectively. Studies done in pure populations of patients with AECOPD, included from the stable phase of the disease with the aim of assessing the effect of suggest the innate immunologic response of different infl ammatory COPD phenotypes. 10, 21, 22 
Prediction of Pneumonia
Currently, an exacerbation of COPD is diagnosed in clinical settings and confi rmed or excluded by means of chest radiograph. However, symptoms of presentation such as fever and productive cough are common in both AECOPD and CAP, and the incidence of pneumonia in patients already cataloged with the diagnosis of AECOPD may be higher. 14 Moreover, a chest radiograph may not be suffi ciently sensitive to identify a new pulmonary infi ltrate. In those cases, physicians often need to request a CT scan, which is not often practical, and prescribe unneeded or nonspecifi c antibiotics.
Our logistic regression model confi rms that the presence of chills, pleuritic pain, and sputum purulence are symptoms predictive of CAP. Based on the rationale of reducing antibiotic prescriptions, the study by Bafadhel et al 23 found that procalcitonin and CRP can independently distinguish pneumonia from exacerbations of asthma or COPD; however, caution has been voiced regarding procalcitonin as diagnostic marker
Characterization of Specifi c Infl ammatory Profi les
In this study, we demonstrated that patients with AECOPD have a different pattern of infl ammatory response to exacerbation, with lower levels of CRP, PCT, TNF-a , and IL-6, especially in the fi rst 3 days after admission. Specifi cally in terms of a long-term infl ammatory response, we note with interest that levels of IL-6 were also higher in patients with CAP 1 COPD at day 30. Neither a higher initial or late inflammatory response in patients with CAP 1 COPD was associated with a higher mortality compared with AECOPD.
We performed three subanalyses of the infl ammatory response, one categorizing the patients according to COPD severity, one excluding patients with AECOPD with potential noninfective cause, and one taking into account prior administration of ICS. We found similar results when analyzing the overall population, with a higher infl ammatory response at days 1 and 3 in patients with CAP 1 COPD and a higher residual infl ammation at day 30 in this population.
Regarding the hypothetical baseline bias of severity of COPD (based on local infl ammation), 17 use of current pharmacotherapy (especially ICS), 18 and presence of an infective etiology in nonpneumonic exacerbations, 19, 20 we found no modulating effect on the measurement of early infl ammatory response (e- in bacterial infection of AECOPD. 24 Signifi cantly, in our study, high levels of CRP on admission to the hospital may help in the diagnosis of one acute event, thereby discriminating patients with CAP 1 COPD from patients with AECOPD ( Figs 4, 5 ). For this reason, we think that quick and easy detection of CRP may be useful in some cases (eg, doubtful infi ltrates, condensation in patients with emphysema), with the possibility of screening for a new pulmonary infi ltrate.
Strengths and Limitations
Although a previous study 14 has compared the clinical manifestations and disease course of AECOPD and CAP 1 COPD, to our knowledge, our study cohort is the fi rst in which two specifi c infl ammatory patterns have been described. Furthermore, diagnosis of COPD performed at least 6 months prior to hospital admission and in a stable phase of the disease was confi rmed by spirometry; this functional approach correctly diagnoses COPD. Another strength is that we were able to follow the patients up to 1 year after discharge.
One limitation is that we did not know the infl ammation levels prior to the acute event in patients with either AECOPD or CAP 1 COPD. Although this may have little clinical relevance, recent publications suggest that some patients with COPD have a chronic profi le of high levels of cytokines. 25 Another limitation of our study is that we did not perform follow-up serial pulmonary function tests and we do not know whether pulmonary functional impairment is similar or different in the two populations.
In conclusion, our study shows that AECOPD and CAP 1 COPD are different acute events in terms of baseline severity, microbiology, and infl ammatory pattern. Although short-term and long-term mortality is similar, we think that patients with CAP 1 COPD should not be categorized as AECOPD, as has been done in several studies.
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